Eli Lilly Expands Pipeline Through Strategic Acquisitions in Diversified Therapeutic Areas
Eli Lilly has been expanding its pipeline through strategic acquisitions outside of its core weight-loss drug focus, including Curevo, LimmaTech Biologics, and The Vaccine Company. These moves aim to strengthen the company's presence in oncology, immunology, neuroscience, pain management, and infectious disease areas.
Tickers: $LLY
Topics: Biotech Pharmaceuticals Pipeline Expansion Weight Loss Drugs